Search for Clinical Trial Results
Neurofibromatosis Type 2 - 1 Studies Found
| Status | Study |
| Completed |
Study Name: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Condition: Malignant Pleural Mesothelioma Date: 2009-12-02 Interventions: Drug: everolimus Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose |